Biomarkers of immune checkpoint inhibitor efficacy in cancer

  • D. E. Meyers University of Calgary; Tom Baker Cancer Centre
  • S. Banerji CancerCare Manitoba

Abstract

Immune checkpoint inhibitor–based therapies that target ctla-4, PD-1, or the PD-1 ligand PD-L1 have received approval in Canada and many parts of the world for the treatment of melanoma, renal cell cancer, urothelial cancer, classical Hodgkin lymphoma, and non-small-cell lung cancer. However only a small proportion of patients derive long-term clinical benefit. Here, we describe the biomarkers associated with the complex relationship between tumour-related immune stimulus, T cell–mediated immune response, and immune modulation of the microenvironment that can help to predict improved patient outcomes.

Author Biography

D. E. Meyers, University of Calgary; Tom Baker Cancer Centre

Department of Oncology

Published
2019-06-25
How to Cite
Meyers, D. E., & Banerji, S. (2019). Biomarkers of immune checkpoint inhibitor efficacy in cancer. Current Oncology, 27(S2). https://doi.org/10.3747/co.27.5549